Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02782104 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
A Phase 3 study of Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,148
- Enrollment target
- 20
- Study locations
NCT02782104: Completed Phase 3 study of Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development.
NCT02782104 is a Phase 3 study of Depressive Disorder, Treatment-Resistant that has completed, run by Janssen Research & Development. The registered enrollment target is 1,148 participants, above the 110-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (944% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02782104, a Phase 3 study of Depressive Disorder, Treatment-Resistant, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,148 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
Primary Outcome
This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of subjects (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. T
Conditions Studied
Interventions
- DRUG Esketamine Nasal Spray
Study Locations (20)
California
- - Garden Grove
- - Glendale
- - Oakland
- - Orange
- - San Diego
- - San Rafael
Illinois
- - Chicago
- - Hoffman Estates
- - Joliet
- - Maywood
- - Skokie
Florida
- - Gainesville
- - Miami
- - Orlando
Connecticut
- - Hartford
- - New Haven
Alabama
- - Birmingham
Arkansas
- - Little Rock
Georgia
- - Atlanta
Iowa
- - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,148 participants |
| Start Date | 2016-06-09 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 3 |
What the finished NCT02782104 record still lists
NCT02782104 is an interventional study that assigns participants to a tested intervention. Its 1,148 participants enrollment target places it among the larger protocols in the corpus, above the 110-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (944% higher).
The record links to 1 condition, with Depressive Disorder, Treatment-Resistant appearing as the primary indexed condition, and to 1 intervention - of which Esketamine Nasal Spray is the first listed.
NCT02782104 names 20 study sites across 8 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT02782104 about?
NCT02782104 is a clinical study titled "A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression". The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
What is the current status of trial NCT02782104?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,148 participants. The study started on 2016-06-09. Estimated completion is 2022-12-30.
What conditions does trial NCT02782104 study?
This clinical trial studies the following conditions: Depressive Disorder, Treatment-Resistant.
What interventions are being tested in trial NCT02782104?
The interventions under investigation include: Esketamine Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02782104?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02782104 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Treatment-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02782104's enrollment target sits among peer trials
1,148 1st of 9 higher than 9 of 9 other Depressive Disorder, Treatment-Resistant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Treatment-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
COMPLETED · Phase 3
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Intravenous Ketamine for Treatment-Resistant Depression
RECRUITING · Phase 2
-
Improving Brain Stimulation Through Imaging
ACTIVE NOT RECRUITING
-
Adaptive tDCS for Treatment-Resistant MDD
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI